CLINICAL MANAGEMENT OF PATIENTS WITH COVID-19. “LIVE” CLINICAL INSTRUCTION (2021)

DOI: https://doi.org/10.31612/covid

DOWNLOAD IN PDF

SUMMARY. In response to the challenges posed by the coronavirus (COVID-19) pandemic, Ukraine has undergone the necessary legislative changes, harmonized with international approaches, which in turn have led to significant changes in health care practices. The Law of Ukraine “On Amendments to Some Legislative Acts of Ukraine on Provision of Treatment of Coronavirus Disease (COVID-19)” № 539-IX, the Order of the Ministry of Health “On Approval of the Procedure for Prescribing and Using Medicines for the Treatment of Coronavirus Disease (COVID-19)” of 30.06.2020 № 1482, registered in the Ministry of Justice of Ukraine on July 08, 2020 for № 641/34924, establish the conditions of use of registered medicines according to the indications not specified in the instructions for medical use (off label), and unregistered medicines, recommended by the relevant official bodies outside Ukraine for the treatment of COVID-19. In pursuance of legislative acts, the Standard of Emergency Care “Coronavirus Disease (COVID-19)”, the Standards of Medical Care “Coronavirus Disease (COVID-19)”, the Standard of Pharmaceutical Care “Coronavirus Disease (COVID-19)”, the Protocol “Provision of medical care for the treatment of coronavirus disease (COVID-19)” were developed, approved and updated in accordance with the established procedure.

At the same time, in order to assist the doctor and the patient in making a rational decision in different clinical situations, a clinical guideline “CLINICAL MANAGEMENT OF PATIENTS WITH COVID-19. “LIVE” CLINICAL INSTRUCTION” was developed – a document containing systematic provisions on medical and medico-social assistance, developed using the methodology of evidence-based medicine on the basis of reliability and proof confirmation. The basis of this clinical guideline is the WHO guideline “Clinical management of COVID-19: interim guidance” (27.05.2020), supplemented by the provisions of other WHO documents, as well as clinical guidelines of Great Britain, Belgium, USA and Australia. This guideline, as a living guideline, is a WHO innovation driven by the urgent need for global collaboration to provide reliable data and guidance emerging in the world as the result of numerous randomized clinical trials on COVID-19. The clinical guideline reflects the sequence of evidence on COVID-19 treatment in the world during a pandemic, on the basis of which the treatment strategy depending on the stage of the disease was formed and the decisions to include and exclude drugs in the protocol for COVID-19 treatment were justified, and will be further updated.

Key words: coronavirus disease (COVID-19), clinical guidelines.